Challenging conventional wisdom on injectables, with Mehul Desai

Countless numbers of commercially viable drug programmes have been abandoned because of a misconception about the limits of subcutaneous drug delivery. That’s the finding of a new survey presented at the AAPS National Biotechnology conference this month.

Mehul Desai, VP of medical affairs at Enable Injections, sat down with pharmaphorum editor-in-chief Jonah Comstock to talk about those startling findings - and also to discuss Enable Injections and its product, an on-body delivery system for large-volume subcutaneous injections called enFuse.

Desai discusses some of the benefits of their system for patient and nurse experience; his company’s product partnerships with Apellis Pharma, Sanofi, Roche, and CSL Behring; and some larger trends in the injectables space.

Finally, Comstock and Desai unpack another piece of conventional wisdom: That patients will always prefer a pill to an injection. Watch the whole video for a fascinating look into the world of injectables.